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Abstract— A microfluidic system for cancer diagnosis based around 
a core MEMS biosensor technology is presented in this paper. The 
principle of the MEMS biosensor is introduced and the 
functionalisation strategy for cancer marker recognition is 
described. In addition, the successful packaging and integration of 
functional MEMS biosensor devices are reported herein. This 
ongoing work represents one of the first hybrid systems to integrate 
a PCB packaged silicon MEMS device into a disposable microfluidic 
cartridge. 
I. INTRODUCTION 
The ability to diagnose cancer at its early stages has a profound 
impact on successful disease treatment. Such early detection in 
clinical diagnostics is now being realised through advances in 
analytical systems and instrumentation miniaturisation [1]. The more 
recent introduction of microfluidic technologies has shown that there 
is great potential to take this positive impact even further by 
enabling the development of point of care systems [2]. This has the 
important potential of significantly reducing the cost of health care 
[3]. The SmartHEALTH Integrated Project consortium is funded by 
the European Commission to address these issues [4]. The system 
presented in this paper is part of the clinical diagnostics instrument 
being developed within the SmartHEALTH project and its main aim 
is to address the necessity for accurate and early detection of several 
types of cancer. 
II. DEVELOPMENT OF A MEMS-BASED CLINICAL DIAGNOSTIC 
SYSTEM 
The diagnostic system being developed relies on a circular 
diaphragm resonator (CDR), MEMS mass sensor, as the central 
theme. This type of sensor is attractive as a new platform technology 
in the first instance due to the sensitivity it yields compared to 
current state of the art mass sensors. The published mass sensitivity 
being 100pg cm-2 Hz-1[5]. In order to create a diagnostic system 
around this central theme a multi-disciplinary team was assembled to 
fabricate the CDR, functionalise the surface at the Nanoscale and 
package the whole concept into a proof of principle cartridge. The 
surface functionalisation research converts the basic CDR into a 
label-free BioMEMS analyte sensor; while the full packaged regime, 
realises a proof of principle test cartridge encompassing all electrical 
contacts and fluidic delivery.  
As an introduction to the principles of the core technology the 
CDR device takes advantage of the degenerate mode resonant mass 
sensor principle [5]. In short, this principle consists of a vibrating 
circular diaphragm, which supports a pair of spatially independent 
modes of vibration sharing a common natural frequency. By 
functionalising the area corresponding to one of these modes with a 
biological capture species e.g. an antibody, but ensuring the 
remaining area remains inert, a biosensor is created. In basic terms, 
target molecules bind to the functionalised area creating a split in the 
resonant frequency of the two modes, which is proportional to a 
change in mass at the surface and, ultimately, analyte concentration. 
This type of structure presents the intrinsic advantage of having a 
reference frequency, to compensate for non-specific effects, within 
the same structure as the functional device thus improving the 
sensitivity of detection. The fact that a reference sensor is not 
required to compensate for pressure and temperature fluctuations is a 
significant advantage over the current state of the art. Fig. 1 presents 
a schematic diagram of this concept.  
 
Fig. 1 Schematic representation of the CDR sensor concept. Four sections of 
the CDR are functionalised, thus providing the ability to capture probe 
biomolecules. The difference in mass on the patterned and non-patterned sections 
creates a frequency split that can be measured. Supplementary addition of mass 
when the target analyte is captured further increases the frequency split. The fact 
that the sample and reference sectors are on the same sensor will auto-compensate 
for temperature and pressure fluctuations maintaining the relative frequency split 
value. 
III. DISPOSABLE CARTRIDGE ASSEMBLY 
The hybrid microfluidic cartridge realisation can be split into three 
strands. A. Microfabrication of the Si/glass CDR device. B. Surface 
functionalisation of the CDR device. C. Packaging the CDR onto a 
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custom designed PCB and integration of the downstream 
components into a polymer microfluidic platform.  This has been 
successfully achieved and a step by step description follows: 
A. MEMS device fabrication 
In order to integrate the CDR device onto a microfluidic platform, 
a new device layout was designed. The current die layout of 2mm x 
2mm is better suited to PCB packaging than the 15mm x 5mm die 
previously presented and designed for dual in-line packaging [6]. 
The CDR device layout and diaphragm details are shown in Fig. 2.  
In the current fabrication process (shown in Fig. 3) the cavity 
underneath the diaphragm was created by reactive ion etching 2µm 
into a 4µm device silicon layer of a SOI wafer. As the diaphragm 
and the cavity walls are made of the same material, the diaphragm is 
perfectly clamped thus ensuring that the flexural displacement of the 
diaphragm at the outer edge is fully constrained - essential for the 
correct performance of the device. This step has been introduced to 
reduce quality issues encountered in earlier manufacturing runs, 
which were created during Si and glass bonding. The fabrication 
process design of the new layout devices was the result of 
collaboration between Newcastle University and Pusan National 
University (PNU), South Korea and was implemented by PNU. 
 
Fig. 2 a) A CDR device (2mm x 2mm) with 20 electrical contact pads for drive 
electrodes, capacitive coupling screening and device silicon biasing. The detail 
shows a 2µm thick diaphragm with a 2µm high cavity which has not yet been 
functionalised. The drive/sense electrodes as well as the screening electrodes can 
be visualized through the diaphragm. b) Image of a diaphragm functionalised with 
3-aminopropyltriethoxysilane (APTES) polymer. 
B. Device functionalisation: surface chemistry and biopatterning 
After much consideration, a hydrophilic polymer was developed 
as the basis for biological functionalisation [7]. Using novel 
conditions for deposition, APTES was shown to form a porous 
polymeric capture network covalently linked to silicon surfaces. The 
porous layer can be deposited with a controlled thickness between 
100 nm and 5 µm, far exceeding the monolayer surface chemistry 
previously reported in the literature [8]. Firstly, the hydrophilic 
nature of the polymer helps to maintain the 3-D structure of 
biomolecules and therefore improves functionality at the sensor 
interface. Secondly, and most importantly, the polymer has 
demonstrated the ability to absorb biomolecules, which should 
increase the dynamic range of the sensor. Finally, the optimised 
chemistry on CDR patterns demonstrated that the immobilisation 
strategy produces highly site-specific and reproducible surfaces for 
both CEA antigen / HPV DNA target recognition.  
 
Fig. 3 CDR device fabrication process flow. Glass wafer processing:  
1. Photolithography and shallow wet etch. 2. Metal deposition. 3. Metal lift-off. 
Silicon on insulator (SOI) wafer (with grown silicon dioxide) processing. 4. 
Lithographic patterning with electrical contact windows and CDR cavities. 5. Dry 
etching (2µm) of device silicon. 6. Resist removal and back oxide etch. 7. SOI to 
glass wafer alignment and anodic bonding. 8. Handle silicon and buried oxide 
removal by dry etching. 9. Gold deposition and lithographic patterning of 
diaphragm electrical contacts. 10. Gold etch. 11. Contact window patterning and 
opening by dry etch. 12. Device functionalisation pattern lithography. 13. APTES 
polymer deposition. 14. APTES polymer lift-off. 
Both species are important markers for cancer diagnostics and will 
be used in conjunction with the polymer and test cartridge in the 
analytical assessment of the proof of principle of the BioMEMS 
clinical diagnostic system. In addition, it has been demonstrated that 
the polymer has wide applicability to bio-molecule capture, 
signposting a new platform technology for generic immobilisation. 
Fig. 4 shows a step-by-step development guide to the surface 
chemistry and its capture capabilities.  It is noteworthy that 
preliminary stability studies have indicated that the polymer is stable 
over a 50 day period and the probe antibody remains stable within 
the polymer matrix for over 50 days at room temperature. 
C. Packaging and integration of the device into a microfluidic 
cartridge 
One of the ultimate aims of the SmartHEALTH project is the full 
integration of the CDR biosensor into a disposable cartridge with 
suitable fluidic and electric interfaces, a challenge, which has been 
tackled by IBMT and MiniFAB in close collaboration. A schematic 
of the packaging concept for the MEMS biosensor is shown in Fig. 
5. As added value to the device development process, the surface 
polymer can be packed with capture biomolecules after full CDR 
packaging is complete, so denaturation of bio-molecules is not a 
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limiting constraint on the packaging concept. This constitutes an 
advantage over conventional sol-gel polymers, which encapsulate 
the biomolecule within their matrix during polymerisation [9].   
 
Fig. 4 Overview of CDR surface chemistry and biopatterning development.  A.) 
A photolithographic mask was manufactured. B.) The mask acts as a stencil to 
divide the CDR diaphragm into four sections of exposed silicon in photoresist 
background. C/D.)  After photoresist removal, S.E.M images demonstrate the 
successful deposition of polymer within the defined CDR pattern. The depth of 
polymer deposition was controllable using different incubation times. E.) A 
characteristically well defined polymer pattern visualised by autofluorescence at 
~ 520nm.  F.) The tagged probe molecule AntiCEA-Alexa647 fluoresces at 650 
nm and shows an identical defined pattern to the underlying polymer layer after a 
short incubation. The four non-recruiting sections can be either left bare or filled 
with a blocking molecule.  G/H.) The two confocal microscopy images of a slice 
taken across a polymer arm indicate that the probe molecule was absorbed 
throughout the porous polymer structure as well as adsorbed at the surface. The 
autofluorescence of the polymer layer indicated a 4µm z-axis height and 
theAntiCEA-Alexa647 absorbed fluorophore indicated a virtually identical height 
I.)The top polymer pattern was activated with native AntiCEA/ blocking solution 
and used to successfully bind CEA tagged with Alexa647. The bottom polymer 
pattern was only backfilled with blocking solution and resulted in no CEA 
recognition. 
 
Fig. 5 Cross-section schematic of hybrid cartridge which incorporates MEMS 
device, PCB packaging and microfluidic network. 
During sensor chip integration and packaging, standard operating 
procedures were developed such that the mechanical stability of the 
diaphragm was not compromised and the functionalising polymer 
was not contaminated. In this process, the first step was to mount the 
MEMS devices onto a recess of a rigid-flex PCB and then establish 
electrical connections for the screening and drive/sense electrodes. 
The CDR sensor was then electrically connected to the PCB using 
microflex, the proprietary interconnection technology of IBMT (Fig. 
6), resulting in a flat surface. The CDR loaded PCB was then 
encapsulated with a biocompatible epoxy layer, whilst leaving the 
functionalised diaphragm area uncovered. This was achieved as 
shown in Fig 7.  
 
Fig. 6 Electrical connection and assembly of the CDR sensors to the rigid PCB 
 
Fig. 7. Epoxy casting concept and device for the coating of the CDR PCB carrier 
with epoxy, while leaving the CDR sensor membranes uncovered. 
The electrical connections between the disposable cartridge and 
the instrument manifold were established through a pogo-pin 
connector with 48 pins, pitched at 0.8 mm, a customized 
development of IBMT. The pogo-pins are double-sided and spring 
loaded to facilitate mounting onto the signal processing board on the 
readout instrument. This arrangement is depicted in Fig. 8. 
 
Fig. 8. Schematic diagram of disposable hybrid cartridge electrical 
connection to the manifold via pogo-pin connector. 
The packaging procedure, was completed when the CDR loaded 
PCB was sandwiched, using a shell and insert principle, into a milled 
polycarbonate microfluidic network that handles reagents and 
delivers the sample to the biosensor. This disposable cartridge 
(shown in Fig. 9a) is then inserted into the instrument manifold, 
developed by MiniFAB (Fig. 9b and 9c). This setup has been 
designed to achieve and withstand a partial vacuum which, as 
reported in [6], is highly desirable. 
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Fig.9 a) Microfluidic cartridge containing the CDR loaded PCB. b) The 
instrument manifold: electrical and fluidic interfaces can be observed. c) 
Microfluidic cartridge clamped on manifold prototype. 
IV. PRELIMINARY TESTING OF THE CDR DEVICE IN A 
MICROFLUIDIC ENVIRONMENT 
Although an ultimate aim of the SmartHEALTH project is to 
develop an instrument, which achieves an electronic readout of the 
signal, the preliminary tests of the CDR biosensor have been carried 
out using electrical stimulation and optical detection. The laser 
Doppler vibrometry test station used has been described previously 
[6]. For the purpose of optical access, a window was incorporated 
into the development prototype cartridge. It is worthy of note that 
the development of the electronic readout is in progress and will 
produce a viable signal amplifier and digital signal processing board.  
In the first instance the fully packaged CDR devices (not 
functionalised) were mechanically tested. These tests were carried 
out in the fluidic reaction chamber under vacuum (0.2mbar). Under 
these conditions, it was found that an unexpected attenuation was 
observed. This attenuation was attributed to the presence of air in the 
device cavity (cavity separating the diaphragm from the electrodes). 
Air was trapped because the epoxy embedding of the die was carried 
out at atmospheric pressure.  As the embedding epoxy covers the 
electrical bond pads, the channels above the metal lines were sealed 
(channels result from the glass etch previous to the gold deposition 
Step 1 in Fig. 3).  This effectively locks air inside the chamber 
underneath the diaphragm, making it impossible to evacuate the 
cavity when the air is pumped out of the rest of the fluidic network. 
In order to confirm this, a CDR was packaged without embedding 
the contact pads in epoxy and then tested at PCB level under vacuum 
(0.2mbar) and at atmospheric pressure. This resulted in a clear 
contrast in the amplitude of the resonance peak as can be seen in Fig. 
10. This was in accordance with what was previously observed 
during characterization of large die devices, in which severe 
vibrational damping was present in devices tested at atmospheric 
pressure [6]. Moreover, a similar damping effect has been reported 
by Pandey et al. [10].  
In order to overcome this damping issue, a CDR device 
embedding process to be carried out under vacuum is currently 
under development. This will allow the production of microfluidic 
cartridges containing CDR devices with low cavity pressure 
(~20mbar) which should have a positive impact on the sensor 
response as previously reported [6].  This final refinement of the 
process will produce fully functional packaged devices, which will 
be used for prototype assay development. 
 
Fig. 10 Comparison of resonance peaks of the CDR device under different 
pressure conditions. 
V. CONCLUSIONS 
The successful fabrication of a new generation of MEMS mass 
sensor devices based on the CDR principle and their subsequent 
packaging and integration onto a disposable microfluidic cartridge 
has been achieved. This hybrid assemblage of PCB packaged silicon 
MEMS and polymer microfluidics represents one of the first of its 
kind. The successful deposition of a bio-functionalizing polymer has 
also been achieved on the MEMS device thus converting it to a 
biosensor, which will be capable of detecting cancer markers at low 
levels. This will allow the SmartHEALTH project to proceed to 
proof of concept assays in the coming months.  
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